))
77: Luís Oliveira: Inovações no tratamento da Doença de Parkinson com a The Michael J. Fox Foundation [PT]
Manage episode 386247400 series 3381015
محتوای ارائه شده توسط André Correia e Daniel Guedelha, André Correia, and Daniel Guedelha. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط André Correia e Daniel Guedelha, André Correia, and Daniel Guedelha یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha dialogam com Luís Oliveira, Senior Associate Director Research Programs na The Michael J. Fox Foundation, abordando a missão inspiradora da fundação, o impacto global das doenças neurodegenerativas em saúde e economia, e estratégias eficazes para mitigar riscos na Doença de Parkinson.
Luis Miguel Oliveira is a Senior Associate Director of Research Programs at The Michael J. Fox Foundation and the Founder of v-ATPase Alliance for rare diseases due to v-ATPase defects.
Luís is an expert in the field of Parkinson's disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets in Parkinson's disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of the v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities to further advance therapeutic development.
With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures.
Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson's disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson's research and drug development fields by enabling an objective characterization of the disease based on its biological features.
Luis Miguel Oliveira's educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York.
Other relevant references | Outras referências relevantes:
Contacts | Contactos:
82 قسمت
اشتراک گذاری
